Streetbeat News

Price Targets

KMX

Truist analyst Scot Ciccarelli maintains a Hold rating on CarMax Inc (NYSE:KMX) with a price target of $72.00. He predicts a 2% decline in Q3 FY24 used unit sales, marking the 8th consecutive quarter of declines. Gross profit estimates were lowered to $619 million from $644 million. CarMax faces affordability challenges with average selling prices 35%-40% higher than in 2019, and monthly payments increased by over 40% due to higher interest rates. Despite a modest decline in used vehicle prices, they remain above historical levels, pressuring sales trends. CarMax Auto Finance also impacts profitability negatively. CarMax will report Q3 results on December 21, 2023.

Portfolio Pulse from Shivani Kumaresan

December 20, 2023 | 7:50 pm

ALRS

Piper Sandler analyst Nathan Race has maintained a Neutral rating on Alerus Financial Corp (NASDAQ:ALRS) and increased the price target from $20 to $23.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:36 pm

TPVG

Piper Sandler analyst Crispin Love has maintained a Neutral rating on TriplePoint Venture Growth (TPVG) and increased the price target from $10 to $11.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:23 pm

SEIC

Piper Sandler analyst Sumeet Mody has maintained a Neutral rating on SEI Investments Company (NASDAQ:SEIC) and increased the price target from $58 to $66.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:22 pm

HTGC

Piper Sandler analyst Crispin Love has maintained an Overweight rating on Hercules Capital (NYSE:HTGC) and increased the price target from $18 to $18.5.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:19 pm

ENFN

Piper Sandler analyst Sumeet Mody has maintained a Neutral rating on Enfusion (NYSE:ENFN) and increased the price target from $9 to $10.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:18 pm

AZN

FUSN

NVS

RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ:FUSN) with an Outperform (Speculative Risk) rating and a $12 price target, indicating a 100% upside potential. The optimism is based on Fusion's competitive position in the radiopharmaceutical industry, which has gained momentum following Novartis AG's (NYSE:NVS) approval for Pluvicto. Fusion's lead program FPI-2265 targets metastatic castration-resistant prostate cancer and could be first-to-market. The company's collaboration with AstraZeneca Plc (NASDAQ:AZN) on FPI-2068 also adds credibility to its platform. FUSN shares rose 4.81% to $6.32.

Portfolio Pulse from Vandana Singh

December 20, 2023 | 7:17 pm

VNO

Piper Sandler analyst Alexander Goldfarb has maintained an Underweight rating on Vornado Realty (NYSE:VNO) but increased the price target from $16 to $25.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:17 pm

SLG

Piper Sandler analyst Alexander Goldfarb has maintained an Overweight rating on SL Green Realty (NYSE:SLG) and increased the price target from $47 to $56.

Portfolio Pulse from Benzinga Newsdesk

December 20, 2023 | 7:15 pm

DGX

Truist Securities analyst David S. MacDonald maintained a Hold rating on Quest Diagnostics (NYSE:DGX) but raised the price target from $145 to $150. The increase reflects strong base business trends, growth opportunities, cost/efficiency initiatives, and potential M&A and partnerships. Despite labor challenges, the company is experiencing core growth, improved pricing, and solid free cash flow (FCF) generation. MacDonald expects margin expansion from 2023 to 2026 and ongoing productivity improvements. He also raised the 2024 EPS estimate to $8.98 while keeping the 2025 estimate at $9.58. DGX shares dropped by 0.81% to $135.35.

Portfolio Pulse from Nabaparna Bhattacharya

December 20, 2023 | 7:14 pm